MICHBIO CONFERENCE & EXPOCELEBRATING 25 YEARS OF

BIO-INDUSTRY GROWTH

SpeakersAlain brings extensive experience in organizational development, manufacturing, R&D, market develop-ment, technology transfer and international expansion to the team. He most recently served as president of an advanced manufacturing company, which was a technology spinout from a large automotive supplier. His activities included marketing and commercialization and leading the advanced R&D activities. The company focused its e�orts in the aerospace, military and transportation industries. Alain has also worked in Europe, Southern Africa, and Central and South America for international corporations such as DuPont, Sherwin Williams and Kongsberg Automotive. He has been involved with turn-around, startup and M&A activities. Alain holds a B.S.B.A. and M.B.A. from Wayne State University.

Anjan Saha is currently an MD/Ph.D. Fellow at the University of Michigan. His graduate work focuses on integrating molecular and informatics methodologies to study human biology and disease. He has also been on the front lines of attacking diabetes in the global space through his work in empowering ancillary care providers in areas where physician shortages are endemic. He will be returning to the clinic in July 2019 in order to complete is medical training after defending his thesis. Anjan co-founded Deoxylytics along with Nikhil Iyer, M.D. and Sumit Gupta, J.D., LL.M. with the goal of bringing informatics solutions to the bedside to facilitate more e�cacious management of chronic disease.

Bill Mayer has founded and exited multiple start-ups in the technology and �nance sectors. His areas of expertise are in �nance, securities and quantitative analysis. He has founded and worked with numerous businesses covering a broad range of industry sectors, ranging from start-up ventures through Fortune 500 companies. Areas of specialty are �nancial modeling, pricing strategies, the process of private and public equity securitization, management of business assets, and fundraising. He has extensive experience in creating �nancial models, business valuations, and capitalization tables, as well as navigating advanced business tax issues and the complex issues surrounding securitization.

Bret Self is the co-founder and CEO of Collective Scienti�c. Bret has been involved with several IT organiza-tions in the last 17 years in industries ranging from �nancial services to data centers to computational chemistry. He has a degree in Computer Science from Michigan Technological University.

Alain Piette, Technology Team Manager, Small Business Center

Anjan Kumar Saha, Co-Founder and CEO, Deoxylitics

Bill Mayer, Vice President of Entrepreneurial Services, Ann Arbor SPARK

Bret Self, CEO, Collective Scienti�c, LLC

Charles earned his doctorate in Molecular Immunology and performed his post-doctoral training in X-ray Crystallography. As an Assistant Professor at UT Southwestern Medical Center in Dallas, he established an NIH-funded laboratory studying immune system-related protein structure and function. He was subse-quently recruited to Parke-Davis Pharmaceuticals in Ann Arbor, MI (later merged with P�zer, Inc) as the Director of structure-based drug design, and via a series of expanding management positions, ultimately joined the Executive Management team with direction over all aspects of drug discovery at the Ann Arbor site, as well as global leadership responsibilities for P�zer’s overall drug discovery technologies. In his capac-ities at P�zer, Dr. Hasemann oversaw several extensive and productive collaborations with biotechnology companies and academic laboratories.

Charles A. Hasemann, PhD, Assistant VP for Innovation and Economic Development at MSU

Christine launched Headlamp Advisors in January 2017 to help healthcare systems move forward with con�dence through strategic planning and helping health systems work better for the communities they serve. Christine has been working with academic medical centers and health systems since 1991 in the US and Canada. Her passion is helping health system reorient their delivery model to be competitive in a value-based reimbursement environment while achieving high value patient outcomes. She believes that good strategy is based on a strong operational foundation, which she brings. Governance, leadership, culture – these areas warrant equal attention and are a signi�cant part of her work with clients. Innovation in delivery models and a strong foundation in operations help Christine apply that knowledge to a fast-changing healthcare market on behalf of the clients she serves.

CELEBRATING 25 YEARS OFBIO-INDUSTRY GROWTH

Christine Stead, CEO, Headlamp Advisors

Speakers

Don Berdahl received his B.S. in Chemistry from the University of Wyoming and his M.S. and Ph.D. degrees in Organic Chemistry from Yale University, studying photooxidation and singlet molecular oxygen. Don was a research scientist at GE’s Corporate Research and Development Center in Schenectady, NY for thirteen years, working in the areas of polymer stabilization, polymer synthesis and environmental chemistry. He served as Manager of the Specialty Chemicals and Modeling Program and, later, the Rapid Field Analysis Program. Don joined Kalsec in 1994 and is currently Exec. VP of Research Strategy and Chief Technical O�cer. Kalsec is a leading producer of spice and herb extracts providing natural �avors, natural colors, oxidation management systems and modi�ed hop extracts to the food and brewing industries. Don is a member of the American Chemical Society and the American Oil Chemists Society and is a past chair of the Lipid Oxidation and Quality Division of the AOCS. He wishes now he had taken more biochemistry courses!

Fred Reinhart is currently Senior Advisor for Technology Transfer in the UMass President’s O�ce. He is a Past President of the Association of University Technology Managers, an international professional organization that supports the commercialization of academic discoveries via out-licensing of intellectual property to industry, creation of high-technology startup companies, and corporate collaboration.

Mr. Hinrichs is a Senior Life Science Banker covering the Midwest United States for J.P.Morgan Chase. He has over 20 years of principal investment, commercial and investment banking experience and has originated and executed over $18 billion of principal investment and lead-agented transaction volume in the capital markets.

Ian is Plymouth’s founding partner and has been active in venture capital investing since 1969. He brings extensive �nancial, operational and technological expertise to Plymouth Growth Partners. Ian formed the �rst institutional VC in Michigan and has led or co-led 14 funds. He has been involved in building over 350 companies, executing over 40 IPOs, and serving on the Board of more than 20 businesses. Successful exits include numerous strategic sales, such as Ventana Medical Systems, Lifescan, Birtcher, Stratacom, and Neogen. Ian received an MBA from Harvard University and a Bachelor of Economics from the University of Sydney. He is an Australian Chartered Accountant.

Don Berdahl, Executive Vice President and Laboratory Director, Kalsec

Fred Reinhart, Sr. Advisor, University Massachusetts Amherst

Hans Hinrichs, Executive Director, Life Science Group, JP Morgan Securities

Ian Bund, Founding Partner, Plymouth Venture Partners

CELEBRATING 25 YEARS OFBIO-INDUSTRY GROWTH

As CEO, Je� is charged with implementing and executing MEDC’s core mission of business development and attraction, community development, providing access to capital and improving Michigan’s image and brand. From 2009 to 2017 Je� was the Executive Director of Michigan’s University Research Corridor which is an alliance between Michigan State University, the University of Michigan, and Wayne State University to transform, strengthen, and diversify Michigan’s economy. Prior to joining the URC, he served as Senior VP and Chief Business Development O�cer for the MEDC. In that role Mason led a team responsible for the retention and expansion of existing Michigan businesses as well as the attraction of national and interna-tional companies to Michigan.

Je� Mason, President and CEO, MEDC

Speakers

Ms. Baird is CEO of Fifth Eye, which is improving quality of care with real-time early warning systems of patient deterioration. Prior to Fifth Eye, Ms. Baird led Accio Energy, focused on rede�ning the wind power industry with Accio’s revolutionary turbine-free Aerovoltaic™ wind energy systems. From 2005 to 2010, Ms. Baird was President and CEO of Accuri Cytometers, a rapidly growing company developing and marketing breakthrough life science products for research and clinical use. Ms. Baird co-founded Accuri and led the company from inception through development and commercialization. She raised over $30 million in venture equity and debt funding and achieved more than $12 million in annual sales, a global reach, and near-pro�tability in just �ve years time. In 2011, Accuri was successfully sold to Becton Dickinson for $205 million (10x revenue), generating 5-6x returns for investors.

Technical leader responsible for leading teams to perform global technology and scouting assessments, in support of Baxter corporate business development and Ventures (~100/yr.); supported >20 acquisitions and partnerships in the range of $300M to $4B. Developed a disciplined process and toolset for managing assessments. Developed a Technology Scouting process driven by user, clinical and business need, creating >30 tech landscapes resulting in several technology partnerships. Jim has more than 35 years of experience in medical device product development, an inventor on 31 issued patents; co-authored a publication in Circulation. Educational background: BS Electrical Engineering (University of Michigan), MS Biomedical Engineering (University of Miami) and MS in Engineering Management (Northwestern University).

Jennifer Baird, Founder and CEO, Fifth Eye

James Martucci, Sr., Director, Baxter International

Jamie Kemler is currently the VP, Intellectual Property Business Strategy for Stryker Corporation with respon-sibility for the development and execution of Stryker’s enterprise-wide IP business strategy to include monetization activities and relationships with technology transfer and licensing/venture o�ces of global universities and hospitals. Prior to this role, Jamie was Group President, Regenerative Medicine. Earlier in his career at Stryker Jamie’s Group President role included responsibility for the Spine, Trauma, and Develop-ment divisions, with multiple manufacturing and research operations in Europe and the U.S.

Jamie Kemler, Vice President, Intellectual Property, Stryker Corporation

Jessica Workman, Corporate Recruiting Manager, Neogen CorporationJessica Workman is the Corporate HR Manager for Neogen Corporation responsible for helping to develop talent management strategies for the organization. Before stepping in to her current role she acted as the Corporate Recruiting Manager for the organization driving talent acquisition initiatives. Jessica started her career within the sta�ng industry focusing on STEM talent and industries. Jessica holds an MBA with a concentration in Human Resource Management and her SPHR certi�cation.

CELEBRATING 25 YEARS OFBIO-INDUSTRY GROWTH

Lisa Simms Booth serves as the Senior Director of Patient and Public Engagement at the Biden Cancer Initia-tive, helping de�ne the organization’s strategic priorities and programs. Lisa leads the Initiative’s advocacy outreach and collaboration strategies, including the design and coordination of the Biden Cancer Collabo-rative which develops solutions to shared challenges.

Lisa Simms Booth, Senior Director of Patient and Public Engagement, Biden Cancer Initiative

Ken Massey, Senior Director, Venture Development, Wayne State University Dr. Ken Massey is the Senior Director for Venture Development, in Technology Commercialization at Wayne State University. Ken has 29 years of biomedical research and business experience in academic, pharmaceu-tical, and biotech arenas. He completed undergraduate studies at Eastern Michigan University and doctoral studies at the University of Texas, Southwestern. He completed two fellowships, Department of Physiology, University of Arizona and the Michigan Hospital Association’s Fellowship in Hospital Governance. Dr. Massey has served on faculty at the UM Medical School, as a director for P�zer, and Managing Director for MicroDose Life Sciences and its venture capital fund, LifeLine Ventures prior to joining Wayne State.

Speakers

Keith Brophy is Director of Business Lab for Blue Cross Blue Shield of Michigan Emerging Markets. Prior to assuming his role at BCBSM, Keith served in a variety of roles across the business, technology and healthcare industries. These include State Director of the Michigan Small Business Development Center; CEO of Ideomed, a chronic disease management digital solution company targeted at Medicaid providers; CEO and co-founder of Sagestone, a transformational custom software solutions company, and as a technologist in System Integration and Research areas at IBM. Keith is a former West Michigan Entrepreneur of the Year, and the various businesses he and his teams built have included national award winning product solutions spanning education, life sciences and health science innovation. Keith has been a national speaker on future trends for many years. Keith has his Bachelors of Science in Computer Science from the University of Michigan in Ann Arbor (where he worked his way through college as an admitting clerk at the U of M Wom-en's Hospital) and his Masters in Information Systems from Strayer University in Washington D.C.

Keith Brophy, Director, Business Lab BCBSM Emerging Markets

As associate vice president for research, technology transfer and innovation partnerships, Sexton provides leadership for the university's innovation and technology transfer activities, along with building partner-ships with public and private entities that are essential to the U-M innovation ecosystem. Sexton previously led the o�ce of technology commercialization and new ventures at North Carolina State University, where she helped create an alumni angel investor network to create a new source of funding for university startups and spinouts. Prior to her arrival at the University of Michigan in January of 2018, Kelly was the assistant vice chancellor for technology commercialization at North Carolina State University. Under her leadership the o�ce doubled the number of licenses and options executed per year, and tripled the number of startup companies launched. She served as principal investigator for an NSF I-Corps site and also led the e�ort to create an alumni angel investor network to provide a new source of funding for university startups and spinouts.

Kelly Sexton, PhD, Associate VP, University of Michigan

Mark Smith, President, MI-HQ

Michael Cole is the President of the Technology Industry Group at Bank of Ann Arbor, a specialized banking practice which he founded in 2002. The group provides banking and �nancial advisory services to more than two hundred technology and life sciences based businesses, venture capital �rms, angel investors, and entrepreneurs in southeastern Michigan. Mr. Cole is the past President of the Ann Arbor Angels, an invest-ment group which he founded, focused on high growth potential, early stage businesses. Prior to joining Bank of Ann Arbor, Michael was a founding member of the Technology Industry Group at Royal Bank of Canada which grew to become a billion-dollar leader in technology sector corporate �nance.

Michael Cole, President Techology Industry Group, Bank of Ann Arbor

Michael Senical, Corporate Strategy and Innovation, Astellas Pharma

Patrick Emerson, Account Executive, Kelly Scienti�c Resources

Marquicia Pierce was trained as a molecular physiologist at Vanderbilt University. Her work this past year and a half has focused on the intersection of business and research for the TIR-199 project. Dr. Pierce recent-ly completed her MBA at Northwood University and brings both management and scienti�c capabilities to the Hibiskus team. In the past �ve years, she has partnered with several life-science companies to support engineers and science leaders with the resources they need to generate and initiate comprehensive strate-gies. Dr. Pierce has championed projects that emphasized program management, FDA regulation planning, �nancial modeling, and market research.

Marquicia Pierce, PhD, MBA - Founder, Ruby Leaf; Program Manager, Hibiskus Biopharm

Seasoned strategy professional with a passion for advancing healthcare. Extensive pharmaceutical and life sciences experience spanning over 14 years in industry and management consulting. Employers and clients ranged from under $1M to over $20B in annual revenue. Broad geographic experience spanning US, EU, Latin America, and Asia/Paci�c. Experienced leader of teams, both local and global. Interested in leveraging technology/digital health to improve outcomes, lower costs, and ultimately deliver more value.

Paul Morris, Chair, MichBio Board of Directors, Global Finance Lead, AlixPartners Mr. Morris currently serves as the global �nance lead for Enterprise Improvement at renowned consulting �rm AlixPartners. Prior to this, he was Director, Operations-Lumigen at Beckman Coulter. He was previously a Senior Manager in the South�eld o�ce of Grant Thornton LLP and a member of the �rm's national Life Sciences Steering Committee. Mr. Morris has worked in a variety of industry settings, primarily life sciences, and led several engagements for biotech and pharmaceutical clients related to operational improvements, �nance and strategy. He holds an MBA from the Tuck School of Business at Dartmouth College and a BBA with First Class Honors from Brock University in St. Catharines, Ontario. In addition to MichBio, he serves on the Board of Vista Maria.

CELEBRATING 25 YEARS OFBIO-INDUSTRY GROWTH

Speakers

Patrick Emerson is an Account Executive with Kelly Scienti�c Resources. He is responsible for business devel-opment as it pertains to scienti�c sta�ng in the areas of Life Science, R&D, Medical Device, Pharma, and Chemical companies throughout the state of Michigan. Along with his biotech and sta�ng industry experi-ence, he works closely with clients to retain, grow, and acquire top scienti�c talent through a consultative approach to workforce solutions. Mr. Emerson has a bachelor’s degree in Biomedical Science from Central Michigan University.

Randel has over 30 years’ experience working in health policy, reimbursement, economics, and dataanalytics for health service, technology and pharmaceutical companies. She presently serves as a Senior Advisor to Boston Biomedical Associates, a leading regulatory and clinical consulting �rm, after completing a senior advisory role at Avalere, Washington DC. Prior to these roles, she successfully founded and sold The Neocure Group, a company providing data analytics, health economics, reimbursement strategic services. For 9 years before founding her own company, she was Vice President, Global Government A�airs, Reim-bursement, Boston Scienti�c Corporation (BSC), establishing the global reimbursement and economics function, expanding to national/international medical device legislative and regulatory, tax, and trade issues.

In his current role as Sr. Director of Strategic Marketing at Stryker, Bob is responsible for advancing organiza-tional competency in understanding global market dynamics and development of strategic direction for growth in the acute medical and pre-hospital markets for the Medical Division. His primary focus is on the establishment of common processes and procedures across the business that advance Stryker Medical’s analytics capabilities, enable early identi�cation of evolving global market opportunities, and drive preemptive actions. Prior to joining Stryker the majority of Bob’s career was spent at Greatbatch Technolo-gies where he worked with the inventor of the implantable pacemaker, Dr. Wilson Greatbatch, on the commercialization of innovative component technologies that signi�cantly impacted performance and market adoption of various implantable medical devices.

Randel Richner, Senior Advisor, Boston Biomedical Associates

Peter Pellerito, SN Policy Adviser & former Interim VP for State Government Relations, BIO

Robert Rusin, Senior Director, Marketing, Stryker Corporation

In his current role, Peter is focused on Federal and State economic development initiatives and tech trans-fer/commercialization. He has co-authored 19 reports and best practices guides on bio and life science economic development legislation and is a contributing author on 7 Battelle/BIO publications focused on state initiatives supporting commercialization. Peter sits on several national committees including the Association of University Technology Managers (AUTM), Association of Public Land-grant Universities (APLU), and American Association of Universities (AAU). Prior to joining BIO, he served as Assistant Vice President for State Government Relations at the University of Michigan, was Chairman of the Ann Arbor Chamber of Commerce Board of Directors, and later worked in government a�airs for two California biotechnology companies.

Robert Kramer, President and COO, Emergent BioSolutions

CELEBRATING 25 YEARS OFBIO-INDUSTRY GROWTH

Speakers

Mr. Kramer was appointed president and chief operating o�cer in March 2018. Prior to his current position, Mr. Kramer served as executive vice president and chief �nancial o�cer from September 2012. Mr. Kramer �rst joined Emergent in 1999 as its CFO. From 1999 until his retirement in 2010, he held various executive positions with the last being president of Emergent Biodefense Operations Lansing. Mr. Kramer returned to the company in 2011 as the interim head of the biosciences division, and then as interim executive vice president, corporate services division. Prior to joining Emergent in 1999, Mr. Kramer held various �nancial management positions at Pharmacia Corporation, which subsequently merged with the Upjohn Company in 1995 and eventually became part of P�zer Inc. Mr. Kramer received an M.B.A. from Western Kentucky University and a B.S. in industrial management from Clemson University.

Scott Merz is a founder and the CEO of MC3 Cardiopulmonary, located in Dexter, Michigan. MC3 is a manu-facturer of devices for the prolonged support of cardiopulmonary function, and currently employs 90 people. In September, MC3 launched a novel jugular cannula to the U.S. market, distributed by Medtronic. Scott received his Ph.D. in Biomedical Engineering from the University of Michigan, and has been involved with the founding and growth of several companies, including Novalung, acquired by Fresenius, and Millipedeay Canada.

Scott Merz, President and CEO, MC3 Cardiopulmonary, Inc

Ron Frisbie has over 30+ years of broad global operational leadership experience in medical device and automotive electronics. Most recently he served as Executive Vice President of Global Operations for CareFusion, responsible for 27 plants and 10,000 people. Ron has had similar roles at Smiths Medical, Medtronic Cardiac Rhythm and Ford Motor Company. Ron holds an MBA and MS in Mechanical Engineering from the University of Michigan, and a BS in Chemical Engineering from Michigan State University.

Ron Frisbie, Chief Operations O�cer, 3T Medical Systems

Ron is Site Leader for P�zer's Kalamazoo Michigan site, a 1,300 acre location with over 4 Million sq. ft. in manufacturing, 150+ Drug products and APIs produced, ~2300 colleagues. He was previously Vice President, Procurement of P�zer’s Global Supply and Global Operations divisions, responsible for P�zer’s production materials and contact manufacturing, supply chain providers, integrated facilities management, capital, energy and services expenditures, and a member of P�zer’s Global Supply Executive Team. Ron serves on P�zer’s Global Women's Council, and co-chairs its Reputation and Inclusion subcommittee. He's a member and previous chair of the Drug, Chemical and Associated Technologies (DCAT) Association's Supply Management Committee, and served two terms on DCAT's Executive Committee as Pharmaceutical Segment Vice President.

Ron Perry, Site head, P�zer Global Supply

Dr. Newton is the Founder and a board member of Esperion Therapeutics. Prior to founding Esperion in 2008, Roger was Senior VP, P�zer Global R&D for four years, the President and CEO of the original Esperion for six years, and Chairman of the Atherosclerosis Drug Discovery Team that developed LipitorR at Warner Lambert for seventeen years. Roger is a fellow of the American Heart Association, director of DeNovo Sciences and Juventas Therapeutics, Inc., and is also a member of the Tech Advisory Boards for Arboretum Ventures and Metagenics, Inc. Roger earned a PhD in Nutrition from the University of California, Davis, an MS in Nutritional Biochemistry from the University of Connecticut, and a BS in Biology from Lafayette College.

Roger Newton, PhD, FAHA, FACN Founder, Esperion Therapeutics

Ron Speagle, Plant Director, RTI Surgical

CELEBRATING 25 YEARS OFBIO-INDUSTRY GROWTH

Speakers

Ron Speagle is a 29 year veteran of manufacturing, engineering and business. His career began in 1989 when he attended GE’s prestigious Manufacturing Management Program. Over the course of Speagle’s career with GE, his excitement for leading change secured him leadership roles in multifaceted sectors of the company: Engineering, manufacturing, marketing, and quality. Most recently, over the last ten years, he led a commercial organization for GE Healthcare across China and Asia Paci�c. In March of 2018 Speagle returned to Michigan, to serve in his current role as Sr. Plant Director, RTI Surgical - Marquette. Ron is excited to be back in the United States and leading growth opportunities in his birth state of Michigan near family and friends. In August of 1995 Speagle obtained his MBA from the Olin School of Business at the University of Washington and has an MS and BA in Electrical Engineering.

Walker is a Co-founder and CEO of PreDxion Bio. PreDxion Bio has been granted Breakthrough Device Desig-nation from the FDA, is backed by Y Combinator, and has received grant funding from the National Institutes of Health. PreDxion Bio is focused on fundamentally changing critical care medicine by leveraging the unique real-time insights into in�ammatory biology provided by their bedside biomarker detection platform to develop best-in-class predictive algorithms and therapeutic decision making support. Walker is a graduate of the University of Michigan, completing undergraduate studies in immunology and further graduate training in the Medical Product Development Program at the University of Michigan College of Engineering. Walker has over ten years of basic science, clinical, and translational research experience, including eight publications, multiple national/international conference presentations, and multiple patent applications.

Walker McHugh, Co-Founder and CEO, PreDxion Bio

Dr. Rapundalo, has broad experience in the life sciences, with an extensive background in pharmaceutical research and development. Prior to joining MichBio in April 2006, he spent almost 20 years as a senior research scientist, project manager, and group leader with Parke-Davis Pharmaceutical Research and then P�zer, Inc., primarily in the area of cardiovascular drug discovery. Dr. Rapundalo also led a global interdisci-plinary team that developed a strategic, operational and organizational change management program to improve P�zer's worldwide R&D business processes. He has a strong background in innovation and is an internationally recognized expert in a number of technology areas including high-throughput screening and proteomics, among others.

Stephen Rapundalo, PhD, President and CEO MichBio

Tim Parker is an entrepreneur and results oriented global business leader with a passion for developing people, products, and processes. 25 years experience in the consumer goods and automotive industries. Broad background in product development, project management, marketing, sales, and operations. Demonstrated ability to drive global change and work cross functionally, moving organizations toward shared beliefs, growth, and pro�table results.

Tim Parker, President, Grand Angels

CELEBRATING 25 YEARS OFBIO-INDUSTRY GROWTH

Speakers